TY - JOUR T1 - POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF OPTIMMISM BY AGE, PRIOR TRANSPLANT, AND HIGH-RISK CYTOGENETICS JO - Hematology, Transfusion and Cell Therapy T2 - AU - Dimopoulos,M. AU - Weisel,K. AU - Moreau,P. AU - Jr,L.D.A. AU - White,D. AU - Miguel,J.S. AU - Sonneveld,P. AU - Engelhardt,M. AU - Jenner,M. AU - Corso,A. AU - Dürig,J. AU - Pavic,M. AU - Salomo,M. AU - Casal,E. AU - Jiang,R. AU - Nguyen,T. AU - Peluso,T. AU - Richardson,P. SN - 25311379 M3 - 10.1016/j.htct.2020.10.454 DO - 10.1016/j.htct.2020.10.454 UR - http://www.htct.com.br/en-pomalidomide-bortezomib-dexamethasone-after-1-articulo-S2531137920307409 ER -